These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38480701)

  • 1. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
    Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
    Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
    Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
    Res Sq; 2023 Jul; ():. PubMed ID: 37502925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
    Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
    Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
    Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
    Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
    Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
    Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
    Liu W; Zhang R; Yu X; Zhang Y; Kang T; Liao D
    Med Oncol; 2023 Aug; 40(9):267. PubMed ID: 37567972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
    Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
    Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER
    Shee K; Jiang A; Varn FS; Liu S; Traphagen NA; Owens P; Ma CX; Hoog J; Cheng C; Golub TR; Straussman R; Miller TW
    FASEB J; 2019 Feb; 33(2):1644-1657. PubMed ID: 30161001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
    Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
    Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
    Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
    Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
    Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
    Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD63
    Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
    Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
    Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
    Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
    Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
    Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.